Bioversys AG - Asset Resilience Ratio

Latest as of December 2024: 17.16%

Bioversys AG (BIOV) has an Asset Resilience Ratio of 17.16% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Bioversys AG (BIOV) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

CHF6.00 Million

≈ $7.59 Million USD Cash + Short-term Investments

Total Assets

CHF34.96 Million

≈ $44.19 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2024–2024)

This chart shows how Bioversys AG's Asset Resilience Ratio has changed over time. See net assets of Bioversys AG for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Bioversys AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BIOV market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF0.00	0%
Short-term Investments	CHF6.00 Million	17.16%
Total Liquid Assets	CHF6.00 Million	17.16%

Asset Resilience Insights

Good Liquidity Position: Bioversys AG maintains a healthy 17.16% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Bioversys AG Industry Peers by Asset Resilience Ratio

Compare Bioversys AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Xizang Haisco Pharmaceutical Group Co Ltd SHE:002653	Biotechnology	2.21%
CSL Ltd AU:CSL	Biotechnology	0.41%
Sk Biopharmaceuticals Co Ltd KO:326030	Biotechnology	0.14%
Crispr Therapeutics AG NASDAQ:CRSP	Biotechnology	74.05%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Ascendis Pharma AS F:A71	Biotechnology	0.00%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%
Hyundai Bioscience Co. Ltd KQ:048410	Biotechnology	13.57%

Annual Asset Resilience Ratio for Bioversys AG (2024–2024)

The table below shows the annual Asset Resilience Ratio data for Bioversys AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	17.16%	CHF6.00 Million ≈ $7.59 Million	CHF34.96 Million ≈ $44.19 Million	--

pp = percentage points

About Bioversys AG

SW:BIOV Switzerland Biotechnology

Market Cap

$199.62 Million

CHF157.90 Million CHF

Market Cap Rank

#17470 Global

#176 in Switzerland

Share Price

CHF27.00

Change (1 day)

-1.10%

52-Week Range

CHF21.50 - CHF35.90

All Time High

CHF36.30